878-61-5

Basic information

• Product Name: 1-BROMO-3-ETHYLADAMANTANE
• Synonyms: 1-BROMO-3-ETHYLADAMANTANE;1-Bromo-3-ethyltricyclo[3.3.1.1(3,7)]decane;1-Ethyl-3-bromoadamantane
• CAS NO: 878-61-5
• Molecular Formula: C₁₂H₁₉Br
• Molecular Weight: 243.18
• Product Categories: Adamantane derivatives;Halides;Ring Systems
• Mol File: 878-61-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 23 °C
• Boiling Point: 124 °C
• Flash Point: 115.6±8.4℃
• Appearance: /
• Density: 1.344±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.0178mmHg at 25°C
• Refractive Index: 1.567
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 1-BROMO-3-ETHYLADAMANTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-3-ETHYLADAMANTANE(878-61-5)
• EPA Substance Registry System: 1-BROMO-3-ETHYLADAMANTANE(878-61-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 878-61-5(Hazardous Substances Data)

Usage

Description

1-BROMO-3-ETHYLADAMANTANE is an organic compound that features a unique adamantane framework with a bromo and ethyl substituent. It is known for its structural rigidity and chemical stability, making it a versatile building block in organic synthesis.

Uses

Used in Pharmaceutical Industry:
1-BROMO-3-ETHYLADAMANTANE is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its adamantane core provides a stable scaffold that can be modified to create new drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
1-BROMO-3-ETHYLADAMANTANE is used as a key building block in the synthesis of 1-adamantyloxyalkanols. These compounds have potential applications in various fields, including the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Chemical Research:
1-BROMO-3-ETHYLADAMANTANE is utilized as a research compound in the study of adamantane-based chemistry. Its unique structure allows chemists to explore new reactions and mechanisms, leading to the discovery of novel synthetic routes and applications.

InChI:InChI=1/C12H19Br/c1-2-11-4-9-3-10(5-11)7-12(13,6-9)8-11/h9-10H,2-8H2,1H3

Upstream product

• 770-69-4 1-ethyladamantane 
• 768-90-1 1-Adamantyl bromide 
• 773-37-5 1-(2-bromo-ethyl)-adamantane 
• 6240-11-5 2-(adamant-1-yl)ethanol 
• 26831-48-1 2-(adamantan-1-yl)ethyl-4-methylbenzenesulfonate 

Downstream Products

• 41100-45-2 1-amino-3-ethyl-adamantane 
• 137910-35-1 (3-Ethyl-1-adamantyl)bis(phenylcarbamoyl)phosphine 
• 137910-36-2 (3,5-Dimethyl-1-adamantyl)bis(p-tolylcarbamoyl)phosphine 
• 101974-67-8 1-ethyl-3-phenyladamantane 
• 1266678-99-2 2-(3-ethyladamant-1-yloxy)ethanol 
• 1266679-00-8 3-(3-ethyladamant-1-yloxy)propan-1-ol 
• 15598-87-5 3-ethyladamantane-1-ol 

Relevant articles and documents

ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION

Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R1, R2, R3, X and Y are defined in the specification.

Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases

A series of memantine nitrate derivatives, as dual functional compounds with neuroprotective and vasodilatory activity for neurodegenerative diseases, was designed and synthesized. These compounds combined the memantine skeleton and a nitrate moiety, and thus inhibited the N-methyl-d-aspartic acid receptor and released NO in the central nervous system. The biological evaluation results revealed that the new memantine nitrates were effective in protecting neurons against glutamate-induced injury in vitro. Moreover, memantine nitrates dilated aortic rings against phenylephrine-induced contraction. The structure-activity relationships of neuroprotection and vasodilation were both analyzed. In further studies, compound MN-05 significantly protected cortical neurons by inhibiting Ca2+ influx, reducing free radical production and maintaining the mitochondrial membrane potential. Further research on MN-05 is warranted.

Adamantane derivatives in the prevention and treatment of cerebral ischemia

A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula STR1 wherein R1 and R2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R3 and R4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R5 is hydrogen or a straight or branched C1 -C6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.